Drugs / SKB105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07380386 | Mar 2026 → Dec 2029 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-01-05 | Crescent Biopharma, Inc. | Regulatory Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors crescentbiopharma.com ↗
Crescent partner Kelun-Biotech receives IND approval for CR-003 (SKB105) by NMPA of China |
| 2026-01-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA kelun-biotech.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-05 | Crescent Biopharma, Inc. | Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors crescentbiopharma.com ↗ |
| 2026-01-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA kelun-biotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07380386 ↗ |
| Modality | Other / unclassified | “SKB105 Antibody-Drug Conjugate(ADC) in solid tumors” NCT07380386 ↗ |
| Route | Intravenous | “iv drip” NCT07380386 ↗ |